Corvus Pharmaceuticals Company Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.

The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases.

It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer.

It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab.

Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

Corvus Pharmaceuticals, Inc.

Country	United States
Founded	2014
Industry	Biological Products, Except Diagnostic Substances
Employees	31
CEO	Richard Miller

Contact Details

Address: 901 Gateway Boulevard South San Francisco, Delaware 94080 United States
Phone	650 900 4520
Website	corvuspharma.com

Stock Details

Ticker Symbol	C17
Exchange	Frankfurt Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Richard Miller	Chief Executive Officer
Leiv Lea	Chief Financial Officer